Vascular Mechanisms of Cerebral Ischemic Tolerance

脑缺血耐受的血管机制

基本信息

  • 批准号:
    7446769
  • 负责人:
  • 金额:
    $ 36.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-07-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Vascular dysfunction and vascular injury, as manifested by impairments in microvascular perfusion, autoregulation, and vascular reactivity, as well as by vasogenic edema, hemorrhage, inflammation, and coagulation, contribute importantly to outcome following focal stroke. Treatment strategies may derive from studies of "ischemic tolerance", wherein endogenous mechanisms of protection are activated by different "preconditioning" stimuli. Studies outlined in this proposal will focus on elucidating the innate mechanisms responsible for protection of cerebrovascular endothelium following hypoxic preconditioning, utilizing a mouse model of induced tolerance to focal stroke and a human cerebrovascular endothelial cell culture model of ischemic tolerance, both developed and characterized in our laboratory. Key induction and expression mechanisms whereby hypoxic preconditioning attenuates diverse endpoints of ischemia-induced vascular/endothelial dysfunction and injury will be elucidated in each model. Specific Aim 1: Elucidate the role of endothelial nitric oxide synthase (eNOS) in the induction and expression pathways responsible for hypoxic preconditioning-induced cerebrovascular ischemic tolerance in vivo and in vitro. We hypothesize that eNOS-derived NO is integral to the signaling pathways responsible for inducing the transcription/translation of vasculoprotective genes. We also hypothesize that eNOS is an effector protein contributing to the ischemia-tolerant phenotype of the preconditioned cerebral microcirculation. Specific Aim 2: Delineate the involvement of the transcription factor HIF-2alpha in mediating cytoprotective gene expression in endothelial cells in vivo and in vitro in response to hypoxic and chemical preconditioning. We will test the hypothesis that the activity of HIF-2alpha, highly expressed in endothelial cells, is upregulated by these preconditioning stimuli, is modulated by eNOS-derived NO and phosphorylated Akt, and is critical to mediating the expression of cytoprotective genes in endothelium that lead to ischemic tolerance. Specific Aim 3: Elucidate the participation of survivin, a specific inhibitor-of-apoptosis family member, in the resistance of in vivo- and in vitro-preconditioned endothelium to ischemic injury, and the mechanisms by which this protein affords protection. We hypothesize that hypoxic preconditioning upregulates survivin expression, which blocks caspase-mediated endothelial injury, thereby preserving post-ischemic microcirculatory homeostasis. Identification of endogenous mechanisms of endothelial cell resistance to ischemic injury may provide novel molecular targets for the therapeutic treatment of vascular dysfunction and vascular injury following focal stroke.
描述(由申请人提供):血管功能障碍和血管损伤,表现为微血管灌注、自动调节和血管反应性受损,以及血管源性水肿、出血、炎症和凝血,对局灶性中风后的结果有重要影响。治疗策略可能源自“缺血耐受”的研究,其中内源性保护机制由不同的“预处理”刺激激活。本提案中概述的研究将重点阐明在缺氧预处理后保护脑血管内皮的先天机制,利用我们实验室开发和表征的局灶性中风诱导耐受的小鼠模型和缺血耐受的人脑血管内皮细胞培养模型。将在每个模型中阐明缺氧预处理减轻缺血引起的血管/内皮功能障碍和损伤的不同终点的关键诱导和表达机制。 具体目标 1:阐明内皮型一氧化氮合酶 (eNOS) 在体内和体外缺氧预处理诱导脑血管缺血耐受的诱导和表达途径中的作用。我们假设 eNOS 衍生的 NO 是负责诱导血管保护基因转录/翻译的信号通路的组成部分。我们还假设 eNOS 是一种效应蛋白,有助于预处理脑微循环的缺血耐受表型。 具体目标 2:描述转录因子 HIF-2α 在体内和体外介导内皮细胞响应低氧和化学预处理的细胞保护基因表达中的作用。我们将检验这样的假设:在内皮细胞中高度表达的 HIF-2α 的活性受到这些预处理刺激的上调,受到 eNOS 衍生的 NO 和磷酸化 Akt 的调节,并且对于介导内皮细胞中导致缺血耐受的细胞保护基因的表达至关重要。 具体目标 3:阐明存活蛋白(一种特异性凋亡抑制剂家族成员)在体内和体外预处理的内皮对缺血性损伤的抵抗中的参与,以及该蛋白提供保护的机制。我们假设缺氧预处理上调生存素表达,从而阻断半胱天冬酶介导的内皮损伤,从而保持缺血后微循环稳态。 内皮细胞抵抗缺血性损伤的内源性机制的鉴定可能为局灶性中风后血管功能障碍和血管损伤的治疗提供新的分子靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFREY M GIDDAY其他文献

JEFFREY M GIDDAY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFREY M GIDDAY', 18)}}的其他基金

Reducing vascular cognitive impairment within and across generations by epigenetic conditioning
通过表观遗传调节减少代内和代际间的血管性认知障碍
  • 批准号:
    10212499
  • 财政年份:
    2021
  • 资助金额:
    $ 36.27万
  • 项目类别:
ENDOGENOUS NEUROPROTECTION IN GLAUCOMA
青光眼的内源性神经保护
  • 批准号:
    7556329
  • 财政年份:
    2008
  • 资助金额:
    $ 36.27万
  • 项目类别:
ENDOGENOUS NEUROPROTECTION IN GLAUCOMA
青光眼的内源性神经保护
  • 批准号:
    8991488
  • 财政年份:
    2008
  • 资助金额:
    $ 36.27万
  • 项目类别:
ENDOGENOUS NEUROPROTECTION IN GLAUCOMA
青光眼的内源性神经保护
  • 批准号:
    7351622
  • 财政年份:
    2008
  • 资助金额:
    $ 36.27万
  • 项目类别:
ENDOGENOUS NEUROPROTECTION IN GLAUCOMA
青光眼的内源性神经保护
  • 批准号:
    8035338
  • 财政年份:
    2008
  • 资助金额:
    $ 36.27万
  • 项目类别:
ENDOGENOUS NEUROPROTECTION IN GLAUCOMA
青光眼的内源性神经保护
  • 批准号:
    7761671
  • 财政年份:
    2008
  • 资助金额:
    $ 36.27万
  • 项目类别:
Ischemic tolerance and endothelial protection
缺血耐受和内皮保护
  • 批准号:
    7454420
  • 财政年份:
    2007
  • 资助金额:
    $ 36.27万
  • 项目类别:
Ischemic tolerance and endothelial protection
缺血耐受和内皮保护
  • 批准号:
    7133836
  • 财政年份:
    2006
  • 资助金额:
    $ 36.27万
  • 项目类别:
Vascular Mechanisms of Cerebral Ischemic Tolerance
脑缺血耐受的血管机制
  • 批准号:
    7248172
  • 财政年份:
    2005
  • 资助金额:
    $ 36.27万
  • 项目类别:
Vascular Mechanisms of Cerebral Ischemic Tolerance
脑缺血耐受的血管机制
  • 批准号:
    6967502
  • 财政年份:
    2005
  • 资助金额:
    $ 36.27万
  • 项目类别:

相似海外基金

Mechanisms that underlie the life/death decisions in a cell that activated apoptotic caspases
细胞中激活凋亡半胱天冬酶的生/死决策的机制
  • 批准号:
    10607815
  • 财政年份:
    2023
  • 资助金额:
    $ 36.27万
  • 项目类别:
Nuclear and chromatin aberrations during non-apoptotic cell death in C. elegans and mammals
线虫和哺乳动物非凋亡细胞死亡过程中的核和染色质畸变
  • 批准号:
    10723868
  • 财政年份:
    2023
  • 资助金额:
    $ 36.27万
  • 项目类别:
Non-apoptotic functions of caspase-3 in neural development
Caspase-3在神经发育中的非凋亡功能
  • 批准号:
    10862033
  • 财政年份:
    2023
  • 资助金额:
    $ 36.27万
  • 项目类别:
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
凋亡供体白细胞促进肾移植耐受
  • 批准号:
    10622209
  • 财政年份:
    2023
  • 资助金额:
    $ 36.27万
  • 项目类别:
Design of apoptotic cell mimetic anti-inflammatory polymers for the treatment of cytokine storm
用于治疗细胞因子风暴的模拟凋亡细胞抗炎聚合物的设计
  • 批准号:
    22H03963
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1
确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制
  • 批准号:
    10537709
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
Activation of non-apoptotic cell death by the DNA damage response
DNA 损伤反应激活非凋亡细胞死亡
  • 批准号:
    10388929
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
Environmental Carcinogens Induce Minority MOMP to Initiate Carcinogenesis in Lung Cancer and Mesothelioma whileMaintaining Apoptotic Resistance via Mcl-1
环境致癌物诱导少数 MOMP 引发肺癌和间皮瘤的癌变,同时通过 Mcl-1 维持细胞凋亡抵抗
  • 批准号:
    10356565
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
  • 批准号:
    10708827
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
  • 批准号:
    10538071
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了